|Dr. Stanislaw R. Burzynski M.D., Ph.D.||Chairman, Chief Exec. Officer and Pres||N/A||N/A||74|
|Mr. Patryk P. Goscianski M.B.A.||Treasurer and Sec.||N/A||N/A||39|
|Dr. Tomasz Janicki M.D.||VP of Clinical Trials||N/A||N/A||51|
Burzynski Research Institute, Inc. operates a research and development facility of drugs used in the treatment of cancer in the United States. The company focuses on the research, development, production, marketing, promotion, and sale of medical chemical compounds, such as growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also provides consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.
Burzynski Research Institute, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.